These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 16954170

  • 1. Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction.
    Ruiz JC, Campistol JM, Sánchez-Fructuoso A, Rivera C, Oliver J, Ramos D, Campos B, Arias M, Diekmann F.
    Nephrol Dial Transplant; 2006 Nov; 21(11):3252-7. PubMed ID: 16954170
    [Abstract] [Full Text] [Related]

  • 2. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L.
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [Abstract] [Full Text] [Related]

  • 3. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
    Sayin B, Karakayali H, Colak T, Sevmis S, Pehlivan S, Demirhan B, Haberal M.
    Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
    [Abstract] [Full Text] [Related]

  • 4. Evolution of proteinuria after conversion from calcineurin inhibitors (CNI) to sirolimus (SRL) in renal transplant patients: a multicenter study.
    Ruiz JC, Diekmann F, Campistol JM, Sanchez-Fructuoso A, Rivera C, Oliver J, Fernandez-Fresnedo G, Arias M.
    Transplant Proc; 2005 Nov; 37(9):3833-5. PubMed ID: 16386555
    [Abstract] [Full Text] [Related]

  • 5. Conversion to sirolimus from cyclosporine may induce nephrotic proteinuria and progressive deterioration of renal function in chronic allograft nephropathy patients.
    Boratyńska M, Banasik M, Watorek E, Falkiewicz K, Patrzałek D, Szyber P, Klinger M.
    Transplant Proc; 2006 Nov; 38(1):101-4. PubMed ID: 16504675
    [Abstract] [Full Text] [Related]

  • 6. Clinical implications of proteinuria in renal transplant recipients switching to rapamycin for chronic allograft dysfunction.
    Gutiérrez MJ, González E, Andrés A, Morales JM.
    Transplant Proc; 2009 Nov; 41(6):2348-50. PubMed ID: 19715916
    [Abstract] [Full Text] [Related]

  • 7. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy.
    Falger JC, Mueller T, Arbeiter K, Boehm M, Regele H, Balzar E, Aufricht C.
    Pediatr Transplant; 2006 Jun; 10(4):474-8. PubMed ID: 16712606
    [Abstract] [Full Text] [Related]

  • 8. Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria.
    Saurina A, Campistol JM, Piera C, Diekmann F, Campos B, Campos N, de las Cuevas X, Oppenheimer F.
    Nephrol Dial Transplant; 2006 Feb; 21(2):488-93. PubMed ID: 16280369
    [Abstract] [Full Text] [Related]

  • 9. Renal function in renal or liver transplant recipients after conversion from a calcineurin inhibitor to sirolimus.
    Bäckman L, Reisaeter AV, Wramner L, Ericzon BG, Salmela K, Brattström C.
    Clin Transplant; 2006 Feb; 20(3):336-9. PubMed ID: 16824151
    [Abstract] [Full Text] [Related]

  • 10. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S, He X, Yang L, Ma Y, Zhu X, Ju W, Huang J.
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [Abstract] [Full Text] [Related]

  • 11. Proteinuria after conversion to sirolimus in renal transplant recipients.
    Sahin GM, Sahin S, Kantarci G, Ergin H.
    Transplant Proc; 2006 Dec; 38(10):3473-5. PubMed ID: 17175308
    [Abstract] [Full Text] [Related]

  • 12. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 13. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
    Stephany BR, Boumitri M, Budev M, Alao B, Poggio ED.
    J Heart Lung Transplant; 2009 Jun 27; 28(6):564-71. PubMed ID: 19481016
    [Abstract] [Full Text] [Related]

  • 14. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.
    Castroagudín JF, Molina E, Romero R, Otero E, Tomé S, Varo E.
    Liver Transpl; 2009 Dec 27; 15(12):1792-7. PubMed ID: 19938140
    [Abstract] [Full Text] [Related]

  • 15. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
    DuBay D, Smith RJ, Qiu KG, Levy GA, Lilly L, Therapondos G.
    Liver Transpl; 2008 May 27; 14(5):651-9. PubMed ID: 18433069
    [Abstract] [Full Text] [Related]

  • 16. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 17. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
    Raichlin E, Khalpey Z, Kremers W, Frantz RP, Rodeheffer RJ, Clavell AL, Edwards BS, Kushwaha SS.
    Transplantation; 2007 Aug 27; 84(4):467-74. PubMed ID: 17713429
    [Abstract] [Full Text] [Related]

  • 18. Conversion to sirolimus for chronic allograft dysfunction: long-term results confirm predictive value of proteinuria.
    Diekmann F, Budde K, Slowinski T, Oppenheimer F, Fritsche L, Neumayer HH, Campistol JM.
    Transpl Int; 2008 Feb 27; 21(2):152-5. PubMed ID: 18005087
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of the efficacy and safety of a slow conversion from calcineurin inhibitor- to sirolimus-based therapies in maintenance renal-transplant patients presenting with moderate renal insufficiency.
    Kamar N, Frimat L, Blancho G, Wolff P, Delahousse M, Rostaing L.
    Transpl Int; 2007 Feb 27; 20(2):128-34. PubMed ID: 17239020
    [Abstract] [Full Text] [Related]

  • 20. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A, Töz H, Sen S, Alkan FT, Nart A, Aykas A, Doğan M, Postaci H, Sahin T, Simşek C.
    Transplant Proc; 2009 Mar 27; 41(2):756-63. PubMed ID: 19328973
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.